RE:Shorters/bottom feeders are so obviousI'm not so sure real investors do understand facts. Telesta had many real investors who yesterday sold 34 mil in Canadian cash, a completed, peer reviewed, very nearly FDA approvable p3 cancer trial, an FDA endorsed pathway for a second P3 and a brand new plant to manufacture it for as low as 18 mil. Less than 30 mil at day's end. Will Telesta see this new trial through? I hope not, but that doesn't diminish its worth and should in fact increase it dramatically. If not named Telesta, somewhere between a conservative 200 - 225 mil was sold for as low as 18 mil yesterday.